Annual EBITDA
-$756.66 M
-$185.26 M-32.42%
31 December 2022
Summary:
Mirati Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$756.66 million, with the most recent change of -$185.26 million (-32.42%) on 31 December 2022. During the last 3 years, it has fallen by -$387.94 million (-105.21%).MRTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$170.94 M
+$15.22 M+8.18%
30 September 2023
Summary:
Mirati Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$170.94 million, with the most recent change of +$15.22 million (+8.18%) on 30 September 2023.MRTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$760.68 M
+$14.79 M+1.91%
30 September 2023
Summary:
Mirati Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$760.68 million, with the most recent change of +$14.79 million (+1.91%) on 30 September 2023.MRTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MRTX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -105.2% | -116.4% | -58.1% |
| 5 y5 years | -638.5% | -199.9% | -329.9% |
MRTX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | >+9999.0% | -1931.5% | >+9999.0% |
Mirati Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | -$170.94 M(-8.2%) | -$760.68 M(-1.9%) |
| June 2023 | - | -$186.16 M(-3.4%) | -$775.47 M(+1.3%) |
| Mar 2023 | - | -$192.75 M(-8.6%) | -$765.82 M(+1.2%) |
| Dec 2022 | -$756.66 M(+32.4%) | -$210.83 M(+13.5%) | -$756.66 M(+1.9%) |
| Sept 2022 | - | -$185.73 M(+5.2%) | -$742.34 M(+16.8%) |
| June 2022 | - | -$176.51 M(-3.9%) | -$635.60 M(+2.0%) |
| Mar 2022 | - | -$183.59 M(-6.6%) | -$622.86 M(+9.0%) |
| Dec 2021 | -$571.40 M(+55.0%) | -$196.51 M(+148.8%) | -$571.40 M(+18.8%) |
| Sept 2021 | - | -$78.98 M(-51.8%) | -$481.02 M(-1.9%) |
| June 2021 | - | -$163.78 M(+24.0%) | -$490.53 M(+19.2%) |
| Mar 2021 | - | -$132.13 M(+24.5%) | -$411.49 M(+11.6%) |
| Dec 2020 | -$368.72 M(+66.2%) | -$106.13 M(+19.9%) | -$368.72 M(+9.4%) |
| Sept 2020 | - | -$88.50 M(+4.4%) | -$337.15 M(+10.3%) |
| June 2020 | - | -$84.73 M(-5.2%) | -$305.65 M(+13.8%) |
| Mar 2020 | - | -$89.36 M(+19.9%) | -$268.50 M(+21.0%) |
| Dec 2019 | -$221.85 M(+116.5%) | -$74.56 M(+30.8%) | -$221.86 M(+25.4%) |
| Sept 2019 | - | -$57.00 M(+19.8%) | -$176.93 M(+18.9%) |
| June 2019 | - | -$47.59 M(+11.4%) | -$148.82 M(+14.6%) |
| Mar 2019 | - | -$42.71 M(+44.2%) | -$129.86 M(+26.8%) |
| Dec 2018 | -$102.45 M(+43.6%) | -$29.63 M(+2.6%) | -$102.45 M(+12.6%) |
| Sept 2018 | - | -$28.89 M(+0.9%) | -$91.01 M(+15.7%) |
| June 2018 | - | -$28.63 M(+87.1%) | -$78.67 M(+14.7%) |
| Mar 2018 | - | -$15.30 M(-15.8%) | -$68.61 M(-3.8%) |
| Dec 2017 | -$71.35 M(-14.7%) | -$18.18 M(+9.8%) | -$71.35 M(-2.2%) |
| Sept 2017 | - | -$16.55 M(-10.9%) | -$72.98 M(-3.9%) |
| June 2017 | - | -$18.57 M(+2.9%) | -$75.97 M(-4.5%) |
| Mar 2017 | - | -$18.05 M(-8.9%) | -$79.58 M(-4.8%) |
| Dec 2016 | -$83.60 M(+29.6%) | -$19.81 M(+1.4%) | -$83.60 M(+1.7%) |
| Sept 2016 | - | -$19.54 M(-11.9%) | -$82.22 M(+1.1%) |
| June 2016 | - | -$22.18 M(+0.6%) | -$81.34 M(+9.0%) |
| Mar 2016 | - | -$22.06 M(+19.7%) | -$74.62 M(+15.7%) |
| Dec 2015 | -$64.50 M(+67.2%) | -$18.43 M(-1.3%) | -$64.50 M(+14.2%) |
| Sept 2015 | - | -$18.67 M(+20.8%) | -$56.47 M(+16.9%) |
| June 2015 | - | -$15.46 M(+29.5%) | -$48.31 M(+12.5%) |
| Mar 2015 | - | -$11.94 M(+14.9%) | -$42.95 M(+11.3%) |
| Dec 2014 | -$38.57 M | -$10.40 M(-1.1%) | -$38.57 M(+10.3%) |
| Sept 2014 | - | -$10.51 M(+4.1%) | -$34.97 M(+4.0%) |
| June 2014 | - | -$10.10 M(+33.4%) | -$33.63 M(+10.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | -$7.57 M(+11.4%) | -$30.38 M(-1.3%) |
| Dec 2013 | -$30.80 M(+51.2%) | -$6.79 M(-25.9%) | -$30.79 M(+1.5%) |
| Sept 2013 | - | -$9.17 M(+33.8%) | -$30.34 M(+11.9%) |
| June 2013 | - | -$6.85 M(-14.1%) | -$27.11 M(+8.6%) |
| Mar 2013 | - | -$7.98 M(+25.6%) | -$24.96 M(+22.5%) |
| Dec 2012 | -$20.38 M(+118.9%) | -$6.35 M(+7.0%) | -$20.38 M(+17.3%) |
| Sept 2012 | - | -$5.94 M(+26.3%) | -$17.37 M(+19.8%) |
| June 2012 | - | -$4.70 M(+38.6%) | -$14.50 M(+27.3%) |
| Mar 2012 | - | -$3.39 M(+1.4%) | -$11.39 M(+19.7%) |
| Dec 2011 | -$9.31 M(-33.4%) | -$3.34 M(+9.0%) | -$9.52 M(+12.9%) |
| Sept 2011 | - | -$3.07 M(+93.0%) | -$8.43 M(-14.0%) |
| June 2011 | - | -$1.59 M(+4.8%) | -$9.80 M(-13.5%) |
| Mar 2011 | - | -$1.52 M(-32.8%) | -$11.33 M(-18.8%) |
| Dec 2010 | -$13.97 M(-34.8%) | -$2.26 M(-49.2%) | -$13.95 M(-16.6%) |
| Sept 2010 | - | -$4.44 M(+42.4%) | -$16.73 M(-1.8%) |
| June 2010 | - | -$3.12 M(-24.6%) | -$17.04 M(-13.3%) |
| Mar 2010 | - | -$4.14 M(-17.7%) | -$19.64 M(-2.0%) |
| Dec 2009 | -$21.43 M(+231.3%) | -$5.03 M(+5.9%) | -$20.05 M(+252.4%) |
| Sept 2009 | - | -$4.75 M(-17.1%) | -$5.69 M(+26.4%) |
| June 2009 | - | -$5.73 M(+26.0%) | -$4.50 M(-24.6%) |
| Mar 2009 | - | -$4.55 M(-148.7%) | -$5.97 M(-13.5%) |
| Dec 2008 | -$6.47 M(-68.8%) | $9.33 M(-362.2%) | -$6.90 M(-68.3%) |
| Sept 2008 | - | -$3.56 M(-50.5%) | -$21.75 M(-9.0%) |
| June 2008 | - | -$7.19 M(+31.3%) | -$23.90 M(+8.3%) |
| Mar 2008 | - | -$5.48 M(-0.7%) | -$22.08 M(+11.8%) |
| Dec 2007 | -$20.73 M(+965.3%) | -$5.52 M(-3.4%) | -$19.75 M(+68.7%) |
| Sept 2007 | - | -$5.71 M(+6.4%) | -$11.71 M(+233.8%) |
| June 2007 | - | -$5.37 M(+70.6%) | -$3.51 M(+199.8%) |
| Mar 2007 | - | -$3.15 M(-224.7%) | -$1.17 M(-34.1%) |
| Dec 2006 | -$1.95 M(-84.1%) | $2.52 M(+1.5%) | -$1.77 M(-78.9%) |
| Sept 2006 | - | $2.49 M(-182.0%) | -$8.40 M(-39.2%) |
| June 2006 | - | -$3.03 M(-19.2%) | -$13.81 M(+2.7%) |
| Mar 2006 | - | -$3.75 M(-8.4%) | -$13.45 M(+12.0%) |
| Dec 2005 | -$12.27 M(+55.9%) | -$4.10 M(+40.4%) | -$12.01 M(+51.8%) |
| Sept 2005 | - | -$2.92 M(+9.2%) | -$7.91 M(+58.6%) |
| June 2005 | - | -$2.67 M(+15.5%) | -$4.99 M(+115.5%) |
| Mar 2005 | - | -$2.31 M | -$2.31 M |
| Dec 2004 | -$7.87 M(+138.8%) | - | - |
| Dec 2003 | -$3.30 M | - | - |
FAQ
- What is Mirati Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Mirati Therapeutics?
- What is Mirati Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Mirati Therapeutics?
- What is Mirati Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Mirati Therapeutics?
What is Mirati Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of MRTX is -$756.66 M
What is the all time high annual EBITDA for Mirati Therapeutics?
Mirati Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$1.95 M
What is Mirati Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of MRTX is -$170.94 M
What is the all time high quarterly EBITDA for Mirati Therapeutics?
Mirati Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $9.33 M
What is Mirati Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of MRTX is -$760.68 M
What is the all time high TTM EBITDA for Mirati Therapeutics?
Mirati Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$1.17 M